Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study

• Ascletis scheduled new data presentations for American Diabetes Association 2026 Scientific Sessions in New Orleans on June 7, 2026.
• Late-breaking preclinical results for ASC39 are set to be presented, supporting its potential as an oral amylin receptor agonist candidate for obesity.
• Phase II findings for oral GLP-1 candidate ASC30 will be presented, indicating meaningful weight loss with improved gastrointestinal tolerability versus placebo.
• Nonhuman primate data for ASC37 oral tablets will be presented, indicating the triple-agonist peptide achieved measurable oral absorption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260430-12137656), on April 30, 2026, and is solely responsible for the information contained therein.